Related Experiment Videos
Somatostatin receptor imaging
Dik J Kwekkeboom1, Eric P Krenning
1Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Abstract:
[(111)In-DTPA(0)]octreotide is a radiopharmaceutical with a great potential for the visualization of somatostatin receptor-positive tumors. The overall sensitivity of Somatostatin Receptor Imaging (SRI) to localize neuroendocrine tumors is high. In a number of neuroendocrine tumor types, as well as in Hodgkin's disease, inclusion of SRI in the localization or staging procedure may be very rewarding, either in terms of cost-effectiveness, patient management, or quality of life. The value of SRI in patients with other tumors, like breast cancer, or in patients with granulomatous diseases, has to be established. The development of Peptide Receptor Radionuclide Therapy (PRRT) is expected to stimulate peptide receptor imaging.
Insights
[(111)In-DTPA(0)]octreotide is a radiopharmaceutical for visualizing somatostatin receptor-positive tumors. Somatostatin Receptor Imaging (SRI) effectively localizes neuroendocrine tumors and may benefit Hodgkin
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmacology
Background:
- [(111)In-DTPA(0)]octreotide is a radiopharmaceutical with potential for visualizing somatostatin receptor-positive tumors.
- Somatostatin Receptor Imaging (SRI) demonstrates high sensitivity in localizing neuroendocrine tumors.
Purpose of the Study:
- To evaluate the utility of SRI in the localization and staging of various tumor types.
- To explore the cost-effectiveness, patient management, and quality of life benefits of incorporating SRI.
Main Methods:
- Utilizes [(111)In-DTPA(0)]octreotide for imaging.
- Applies Somatostatin Receptor Imaging (SRI) techniques.
Main Results:
- SRI shows high sensitivity for neuroendocrine tumor localization.
- SRI can be beneficial in staging neuroendocrine tumors and Hodgkin's disease.
- The value of SRI in breast cancer and granulomatous diseases requires further investigation.
Conclusions:
- SRI is a valuable tool for specific tumor types, improving patient management and quality of life.
- Further research is needed to establish SRI's role in other conditions.
- Advancements in Peptide Receptor Radionuclide Therapy (PRRT) are anticipated to drive growth in peptide receptor imaging.